WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009059943) 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/059943    International Application No.:    PCT/EP2008/064859
Publication Date: 14.05.2009 International Filing Date: 03.11.2008
IPC:
C07D 401/12 (2006.01), C07D 401/14 (2006.01), C07D 413/14 (2006.01), A61K 31/5377 (2006.01), A61P 3/06 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH) (For All Designated States Except US).
MOGI, Muneto [JP/US]; (US) (For US Only).
YAMADA, Ken [JP/US]; (US) (For US Only).
YASOSHIMA, Kayo [JP/US]; (US) (For US Only).
KAWANAMI, Toshio [JP/US]; (US) (For US Only).
UMEMURA, Ichiro [JP/JP]; (JP) (For US Only).
IWAKI, Yuki [JP/US]; (US) (For US Only).
QIN, Hongbo [CN/JP]; (JP) (For US Only).
IMASE, Hidetomo [JP/US]; (US) (For US Only)
Inventors: MOGI, Muneto; (US).
YAMADA, Ken; (US).
YASOSHIMA, Kayo; (US).
KAWANAMI, Toshio; (US).
UMEMURA, Ichiro; (JP).
IWAKI, Yuki; (US).
QIN, Hongbo; (JP).
IMASE, Hidetomo; (US)
Agent: VÖGELI-LANGE, Regina; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH)
Priority Data:
60/985,456 05.11.2007 US
Title (EN) 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS
(FR) DÉRIVÉS DE 4-BENZYLAMINO-1-CARBOXYACYL-PIPÉRIDINE EN TANT QU'INHIBITEURS DE CETP UTILES POUR LE TRAITEMENT DE MALADIES TELLES QUE L'HYPERLIPIDÉMIE OU L'ARTÉRIOSCLÉROSE
Abstract: front page image
(EN)The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
(FR)La présente invention concerne un composé représenté par la formule (I) : les variants R1, R2, R3, R4, R5, R6, R7 étant tels qu'ils sont définis dans le présent document. Ledit composé est un inhibiteur de CETP et peut donc être utilisé pour le traitement d'un trouble, ou d'une maladie, médié par CETP ou sensible à l'inhibition de CETP.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)